FDA Approves Lenalidomide Capsules in 2.5mg, 20mg Strengths
The company also received tentative approval for the 5mg, 10mg, 15mg, and 25mg strengths.
Multiple Myeloma News
MULTIPLE MYELOMA ADVISOR
Multiple Myeloma News
Younger Age at Diagnosis May Predict Higher VTE Risk in Patients With Multiple Myeloma
Researchers sought to determine whether higher-intensity thromboprophylaxis may be necessary for reducing the risk of VTE in younger patients with multiple myeloma.
Salvage Autologous Stem Cell Transplantation May Improve Outcomes for Relapsed/Refractory Multiple Myeloma
Researchers sought to determine whether salvage therapy with high-dose chemotherapy followed by ASCT would improve survival in patients with MM.
Utilization Patterns Explain Nonadherence to Treatment for Multiple Myeloma, CML, Some Metastatic Cancers
A retrospective study of Medicare data showed a potential factor in nonadherence to oral cancer treatment regimens.
How to Prevent a Cyberattack from Derailing Cancer Care
Cyberattacks on health care organizations may not be fully preventable, but there are ways to limit their impact on cancer care.
Prognostic Importance of Extramedullary Lesions in Multiple Myeloma
Researchers sought to determine whether extramedullary lesions would be an indicator of prognosis in patients with multiple myeloma treated in the first line with bortezomib.
Updated Safety and Efficacy of CAR T-Cell Therapy Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
A single dose of cilta-cel yielded early, deep, and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma.
How Prior Alkylator Exposure Impacts the Efficacy of Melflufen in Multiple Myeloma
Patients with fewer prior lines of therapy in which they were exposed or refractory to alkylators generally had better outcomes.
Carfilzomib Combination Therapy Effective for Patients With Multiple Myeloma
Researchers sought to determine whether therapy with carfilzomib, lenalidomide, and dexamethasone would be effective for patients with newly diagnosed multiple myeloma.
Upfront Daratumumab Shows Survival Benefit in Combination for Transplant-Ineligible Multiple Myeloma
Researchers sought to determine if there would be a survival benefit with daratumumab combined with lenalidomide and dexamethasone in patients with transplant-ineligible MM.
Isatuximab Improves PFS in Elderly Patients with Relapsed Multiple Myeloma
Adding isatuximab to carfilzomib and dexamethasone also improved the depth of response.
Neuropsychiatric Disorders Common in Patients Who Receive CAR-T Therapy for Multiple Myeloma
Researchers sought to determine whether there was an association between NPDs and CAR-T therapy in patients with multiple myeloma.
Real-World Data Confirm Poor Survival in Triple-Exposed Multiple Myeloma
After initial triple-class exposure, most patients received a combination of triple-class agents and other agents.
Patients on Trials Supporting Drug Approvals Are Younger Than Real-World Patients
The median age of trial participants was 3.8 years younger than the median age of the real-world population.
SARS-CoV-2 mRNA Vaccine Responses in Patients With Multiple Myeloma
Patients with active multiple myeloma may have insufficient responses to mRNA COVID-19 vaccines.
Outcome Improvements With Ixazomib and Dexamethasone in Relapsed or Refractory Systemic Light Chain Amyloidosis
Researchers sought to determine whether ixazomib and dexamethasone would be more effective vs physician’s choice of treatment in relapsed or refractory AL amyloidosis.
Balancing CD38 Expression May Affect Response to Daratumumab in Patients With Multiple Myeloma
Researchers sought to determine whether balancing expression of CD38 on target and effector cells may improve therapy response to daratumumab in patients with multiple myeloma.
Daratumumab-Based Regimens Associated With Sustained MRD Negativity in Multiple Myeloma
Patients who received daratumumab were more likely to be MRD negative at 12 months and beyond.
CHIP May Affect Some Outcomes in Patients Receiving CAR T-Cell Therapy
CHIP was associated with higher rates of complete response and cytokine release syndrome.
Short WBMRI Protocol May Be Viable for Bone Infiltration Evaluation in Patients With Multiple Myeloma
Researchers sought to determine whether a short WBMRI protocol would reduce the length of MRI tests while maintaining high sensitivity and specificity for patients with multiple myeloma.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Multiple Myeloma News
Loading... 
Loading...